As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
The content of toxicokinetic studies in different toxicity tests, such as the frequency of exposure monitoring and characterization, can be increased or decreased according to research needs. The toxicokinetic studies of various toxicity tests are considered as follows:
The toxicokinetic results of a single-dose toxicity test help evaluate and predict the choice of dosage form and the exposure rate and duration after administration, as well as for selecting appropriate dosage levels in subsequent studies.
The content of toxicokinetic studies should generally be included in the repeated dosing toxicity test design, which provides for regular exposure monitoring and characteristic studies from the first to the end of the administration. The protocol used in the subsequent toxicity test can be revised or adjusted based on the results of the toxicology study of the previous test. When there are unexplainable toxicity problems in early toxicity tests, it may be necessary to extend or shorten the time for toxicity monitoring and character studies of the test substance or to revise the research content.
We boast complete pharmacokinetic, toxicokinetic and analytical research facilities and instruments. Our Toxicology Research Department has been granted AAALAC Accreditation and GLP certificate of NMPA and passed the on-site evaluation, with research globally-recognized capabilities to support filing programs for multiple countries.
When the result of the in vivo genotoxicity test is negative, it is necessary to combine the exposure data to evaluate the genotoxicity.
Sexual risk, especially when the in vitro test shows a clear positive result or the in vitro mammalian cell test has not been performed.
The assessment of in vivo exposure should use the same animal species, strain, and route of administration as the genotoxicity test at the highest dose or other relevant doses. In vivo exposure can be shown by the test.
In vivo cytotoxicity (such as a significant change in the ratio of immature red blood cells to the total number of red blood cells in the tissue detected in the micronucleus test) or exposure (measuring the direction of the test substance and its metabolites in the blood or plasma, or directly Measure the direction of the test substance and its metabolites in the target tissue) to prove.
If the in vitro genotoxicity test results are negative, the above methods can be used for other purposes.
The rodent pharmacokinetics/toxicity tests' results were evaluated in conjunction with in vivo exposure.
The purpose of the reproductive toxicity toxicokinetics study is to analyze the results of the reproductive toxicity test.
It helps to determine whether the doses in the reproductive toxicity test stages have reached sufficient exposure. The possible differences in the dynamic characteristics of animals during pregnancy and non-pregnancy should be considered.
The toxicokinetic data can come from all animals in the reproductive toxicity test or from some animals. Toxicokinetic data should include fetal/pup data to evaluate the test substance and metabolic production.
The substance can pass through the placental barrier and milk secretion.
marketing@medicilon.com
ABOUT
